Investment Rating - The report maintains a "Buy" rating for the company with a target price of 16.75 yuan [4][5]. Core Views - The company's profitability has significantly improved, with emerging fields such as foldable machines contributing to growth momentum. The company is expected to maintain high-speed growth due to developments in various sectors, including foldable machines and AI servers [3][4]. Financial Performance Summary - The company reported a revenue of 2.353 billion yuan for the first half of 2024, representing a year-on-year increase of 33.50%. The net profit attributable to shareholders reached 190 million yuan, up 431.53% year-on-year, while the net profit after deducting non-recurring items was 178 million yuan, a staggering increase of 6821.68% [4]. - Revenue breakdown by segments shows that P&S revenue was 1.111 billion yuan (up 26.69% year-on-year), SMC revenue was 456 million yuan (down 6.52% year-on-year), and MIM revenue was 767 million yuan (up 101.11% year-on-year) [4]. - The gross margins for the three main segments were 25.56%, 21.77%, and 24.30%, reflecting increases of 6.08 percentage points, 10.88 percentage points, and 2.49 percentage points respectively [4]. Growth Drivers - The growth in the MIM segment is attributed to the increasing demand for foldable machine hinges, with the company currently operating five production lines for foldable machine hinge modules. The company is also expanding its presence in the titanium powder market for 3D printing and titanium metal powder forming [4]. - The company has successfully developed high-speed connector covers for servers, with one product already in mass supply, indirectly supporting NVIDIA's GB200NVL72 server [4]. Market Outlook - The report highlights that the penetration rate of foldable screens is continuously increasing, and the company has successfully validated new product numbers, which are expected to act as catalysts for future growth [4].

海 外 公 司 （ 中 国 香 港 ） 国泰君安版权所有发送给上海东方财富金融数据服务有限公司.东财接收研报邮箱.ybjieshou@eastmoney.com p1 业绩超预期，胶原棒高增、敷料渠道拓展 巨子生物(2367) 家庭及个人用品 [Table_Industry] [Table_Invest] 评级： 增持 ——巨子生物 2024H1 业绩点评 | --- | --- | --- | --- | |----------|------------------|----------------------|-------------------| | | 訾猛(分析师) | 闫清徽(分析师) | 杨柳(分析师) | | | 021-38676442 | 021-38031651 | 021-38038323 | | | zimeng@gtjas.com | yanqinghui@gtjas.com | yangliu@gtjas.com | | 登记编号 | S0880513120002 | S0880522120004 | S0880521120001 | 本报告导读： 公司 24H1 业绩超预期， ...

股 票 研 究 证 券 研 究 报 告 ——中报点评 | --- | --- | --- | |----------|-------------------------------------|----------------------| | | | | | | [table_Authors] 王彦龙 ( 分析师 ) | 黎明聪 ( 分析师 ) | | | 010-83939775 | 0755-23976500 | | | wangyanlong@gtjas.com | limingcong@gtjas.com | | 登记编号 | S0880519100003 | S0880523080008 | 本报告导读： 维持盈利预测和目标价，维持增持评级; 业绩符合预期，芯片及器件业务高速增 长； 布局光引擎相关芯片组件赛道，有源芯片各有进展。 投资要点： [Table_Summary] 维持盈利预测和目标价，维持增持评级。公司公告 2024 年中报，中 报业绩与此前预告相符，整体符合预期。我们维持 2024-2026 年归 母净利润为 0.51/1.20/2.15 亿元，对应 EPS 为 0.11\0.26\ ...

——2024 年中报点评 吨价表现亮眼，Q2 收入环比提速 燕京啤酒(000729) 食品饮料 [Table_Industry] /必需消费 | --- | --- | --- | |-----------------------------|-----------|-------| | [Table_Invest] 评级： | | 增持 | | | 上次评级: | 增持 | | [Table_Target] 目标价格： | | 12.17 | | | 上次预测: | 12.17 | | [当前价格： Table_CurPrice] | | 9.83 | | --- | --- | |----------|--------------------| | | 陈力宇(分析师) | | | 021-38677618 | | | chenliyu@gtjas.com | | 登记编号 | S0880522090005 | 本报告导读： 公司改革提效成果不断凸显，在 U8 大单品持续放量带动下结构提升显著、吨价表 现优异，同时吨成本下行，24Q2 收入环比加速、盈利弹性明显释放。 投资要点： 证 券 研 究 报 告 ...

股 票 研 究 [table_Authors] 徐强(分析师) 邵潇(分析师) 于歆(分析师) 010-83939805 0755-23976520 021-38038345 xuqiang@gtjas.comshaoxiao@gtjas.com 登记编号 S0880517040002 S0880517070004 S0880523050005 2024 年中报点评 yuxin024466@gtjas.com 本报告导读： 2024Q2 环比扭亏，营收与净利润均实现同比增长，公司经营逐季改善。公司提升碳 计量业务子公司持股比例，加速碳计量业务布局。 投资要点： [Table_Summary] 维持"增持"评级。根据公司 2024H1 经营情况，我们下调公司 2024- 2026 年归母净利润预测分别为 2.12/2.45/2.86 亿元（原 2.37/2.80/3.57 亿元），对应 EPS 分别为 0.33、0.39、0.45 元。根据可比分析仪器公 司 2025 年 PE 均值 22 倍，给予公司 2025 年 22 倍 PE，下调目标价 至 8.53 元（原 10.28 元），维持"增持"评级。 业绩基 ...

股 票 研 究 股票研究 /[Table_Date] 2024.08.20 证 券 研 究 报 告 -13% 6% 24% 42% 60% 78% 2023-08 2023-12 2024-04 本报告导读： [Table_Market] 交易数据 投资要点： [Table_PicQuote] 52周股价走势图 国电电力 上证指数 [Table_Report] 相关报告 [当前价格： Table_CurPrice] 5.53 优质火电盈利突出，资产出售增厚业绩 国电电力(600795) [Table_Industry] 电力/公用事业 | --- | --- | --- | |---------------------------|-----------|-------| | [Table_Invest] 评级： | | 增持 | | | 上次评级: | 增持 | | [Table_Target] 目标价格： | | 7.20 | | | 上次预测: | 7.20 | | --- | --- | --- | --- | |----------|-----------------------------|--- ...

AI 引领持续高增长，算力芯片稳步推进 AMD(AMD.US) [Table_Industry] 海外信息科技 [Table_Invest] 评级： 增持 ——超威半导体 FY24 Q2 业绩点评 [table_Authors] 秦和平(分析师) 0755-23976666 qinheping027734@gtjas.com 登记编号 S0880523110003 本报告导读： 营收利润均超预期，下季度指引提升；微软扩大 MI300X 应用，AMD 计划 GPU 芯 片稳定迭代；CPU 落地良好，Q3Zen5 推出将带来新增量。 投资要点： [Table_Summary] 盈利预测与投资建议：短期看，云厂商高 capex 支撑需求；长期看， 芯片产品路线逐年升级。我们小幅调整公司 FY2024E-FY2026E 的 营业收入为 259.2/329.2/391.8 亿美元（前值为 270.5/337.0/404.0 亿 美元）；对应小幅调整 NON-GAAP 净利润为 62.7/96.4/115.7 亿美元 （前值为 56.8/86.57/145.9 亿美元）。基于 FY2025 P/E 30x，给予 FY20 ...

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 39.79 RMB [5] Core Viewpoints - The company demonstrates steady performance growth, with its innovation pipeline expected to gradually materialize, indicating long-term growth potential [4] - The company's profitability has improved, with a gross margin of 32.70% (+0.97pct) and a net margin of 8.05% (+0.99pct) in H1 2024 [9] - The innovation pipeline is progressing well, with 129 R&D projects, including 86 innovative drugs and biosimilars, expected to yield results in the near future [9] Financial Performance - H1 2024 revenue reached 20.965 billion RMB (+2.84%), with net profit attributable to shareholders of 1.696 billion RMB (+18.29%) [9] - Q2 2024 revenue was 10.554 billion RMB (+2.76%), with net profit attributable to shareholders of 834 million RMB (+22.85%) [9] - The pharmaceutical industrial segment contributed 6.698 billion RMB (+10.63%) in revenue, while the medical aesthetics segment generated 1.348 billion RMB (+10.14%) [9] Innovation Pipeline - Key products such as liraglutide injection for diabetes and weight loss, BCMA CAR-T, and ELAHERE are expected to be approved or achieve milestones in 2024 [9] - The oral small molecule GLP-1 receptor agonist HDM1002 completed Phase II clinical trials for overweight or obesity in August 2024, with top-line results expected in Q4 2024 [9] Market Data - The company's market capitalization stands at 53.735 billion RMB, with a 52-week stock price range of 26.38-42.98 RMB [6] - The company's P/E ratio is 21.50x for 2022, 18.93x for 2023, and is expected to decrease to 15.83x in 2024 [10] Financial Forecasts - Revenue is projected to grow from 43.826 billion RMB in 2024 to 51.664 billion RMB in 2026, with a CAGR of 7.8% [10] - Net profit attributable to shareholders is expected to increase from 3.394 billion RMB in 2024 to 4.475 billion RMB in 2026 [10] - The company's ROE is forecasted to remain stable at around 14.2%-14.6% from 2024 to 2026 [10]

股 票 研 究 股票研究 /[Table_Date] 2024.08.20 行 业 周 报 证 券 研 究 报 告 7 月数据相对平淡，区域热点关注提升 [Table_Industry] 建材 [Table_Invest] 评级： 增持 上次评级: 增持 | --- | --- | --- | --- | |----------|---------------------|---------------------|---------------------------| | | 鲍雁辛(分析师) | 花健祎(分析师) | 巫恺洋(研究助理) | | | 0755-23976830 | 0755-23976858 | 0755-23976666 | | | baoyanxin@gtjas.com | huajianyi@gtjas.com | wukaiyang028675@gtjas.com | | 登记编号 | S0880513070005 | S0880521010001 | S0880123070145 | 本报告导读： 7 月数据整体保持平淡，本周我们发布西藏水泥专题报告解读西南水泥行业供需变 化趋 ...

股 票 研 究 ——创世纪 2024 年半年报点评 | --- | --- | --- | |----------|-------------------------------------|-------------------------| | | [table_Authors] 徐乔威 ( 分析师 ) | 李启文 ( 分析师 ) | | | 021-38676779 | 021-38038435 | | | xuqiaowei023970@gtjas.com | liqiwen027858@gtjas.com | | 登记编号 | S0880521020003 | S0880524060001 | 本报告导读： 业绩符合预期，Q2 业绩改善明显；AI 与新工艺为 3C 注入新活力，设备更新推动新 一轮机床更新；发力高端五轴，拥抱海外及通用市场。 投资要点： 证 券 研 究 报 告 [Table_Summary] 投资建议：考虑到 AI 端侧落地加速及公司海外、五轴业务进展加 速，上调 24-26 年 EPS 为 0.29/0.36/0.42 元（原 0.27/0.33/0.39 元）， 维持目标价 8. ...